[go: up one dir, main page]

CO2017012675A2 - Péptidos lipidados resistentes a proteasas - Google Patents

Péptidos lipidados resistentes a proteasas

Info

Publication number
CO2017012675A2
CO2017012675A2 CONC2017/0012675A CO2017012675A CO2017012675A2 CO 2017012675 A2 CO2017012675 A2 CO 2017012675A2 CO 2017012675 A CO2017012675 A CO 2017012675A CO 2017012675 A2 CO2017012675 A2 CO 2017012675A2
Authority
CO
Colombia
Prior art keywords
peptides
protein resistant
lipid peptides
protease
resistant lipid
Prior art date
Application number
CONC2017/0012675A
Other languages
English (en)
Inventor
Jefferson D Revell
Maria A Bednarek
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CO2017012675A2 publication Critical patent/CO2017012675A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona péptidos resistentes a proteasas, métodos de preparación de tales péptidos, así como composiciones que comprenden péptidos resistentes a proteasas y métodos de tratamiento que utilizan tales péptidos. Una combinación de lipidación de determinados residuos de aminoácidos y sustitución de aminoácidos funcionalizados con alfa-metilo en lugar de aminoácidos naturales para producir péptidos resistentes a proteasas.
CONC2017/0012675A 2015-06-10 2017-12-11 Péptidos lipidados resistentes a proteasas CO2017012675A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562173631P 2015-06-10 2015-06-10
US201662343390P 2016-05-31 2016-05-31
PCT/EP2016/063206 WO2016198544A1 (en) 2015-06-10 2016-06-09 Protease-resistant lipidated glp-1 analogs

Publications (1)

Publication Number Publication Date
CO2017012675A2 true CO2017012675A2 (es) 2018-02-28

Family

ID=56235790

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0012675A CO2017012675A2 (es) 2015-06-10 2017-12-11 Péptidos lipidados resistentes a proteasas

Country Status (25)

Country Link
US (3) US10414811B2 (es)
EP (2) EP3865504A1 (es)
JP (1) JP6811190B2 (es)
KR (1) KR20180016441A (es)
CN (1) CN108271373B (es)
AU (2) AU2016277449B2 (es)
CA (1) CA2988841C (es)
CL (1) CL2017003144A1 (es)
CO (1) CO2017012675A2 (es)
CR (1) CR20170559A (es)
DO (1) DOP2017000287A (es)
EA (1) EA036415B1 (es)
ES (1) ES2849950T3 (es)
IL (1) IL255978B (es)
MX (1) MX2017015482A (es)
MY (1) MY185816A (es)
NI (1) NI201700156A (es)
NZ (1) NZ738909A (es)
PE (1) PE20180659A1 (es)
PH (1) PH12017502259A1 (es)
SG (1) SG10201911837SA (es)
SV (1) SV2017005585A (es)
TN (1) TN2017000519A1 (es)
TW (1) TWI726889B (es)
WO (1) WO2016198544A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468987A2 (en) * 2016-06-09 2019-04-17 Medimmune Limited Protease-resistant mono-lipidated peptides
CN111655338A (zh) * 2017-10-31 2020-09-11 免疫医疗有限公司 Glp-1肽类似物的口服递送
HUE067499T2 (hu) 2018-04-05 2024-10-28 Sun Pharmaceutical Ind Ltd Új GLP-1 analógok
EP4281464A4 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
JP2006501820A (ja) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
KR20080052649A (ko) * 2005-09-08 2008-06-11 트러스티즈 오브 터프츠 칼리지 안정화된 ｇｌｐ―1 유사체
ATE444741T1 (de) * 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
ATE554098T1 (de) 2007-12-11 2012-05-15 Cadila Healthcare Ltd Peptidomimetica mit glucagon-antagonistischen und glp-1-agonistischen aktivitäten
WO2010063818A2 (en) * 2008-12-05 2010-06-10 Glaxo Group Limited Methods for selecting protease resistant polypeptides
IN2012DN00377A (es) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
US20130143800A1 (en) 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EP3287172A1 (en) 2012-12-06 2018-02-28 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
EP3238734A1 (en) * 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
KR20160098406A (ko) 2013-12-13 2016-08-18 메디뮨 리미티드 프로테아제 내성 펩티드

Also Published As

Publication number Publication date
EA201792640A1 (ru) 2018-06-29
EP3865504A1 (en) 2021-08-18
DOP2017000287A (es) 2018-04-15
IL255978A (en) 2018-01-31
US20180162920A1 (en) 2018-06-14
AU2016277449B2 (en) 2019-06-20
NZ738909A (en) 2019-08-30
CA2988841A1 (en) 2016-12-15
US20200079833A1 (en) 2020-03-12
TW201710287A (zh) 2017-03-16
PE20180659A1 (es) 2018-04-17
NI201700156A (es) 2018-10-18
MX2017015482A (es) 2018-02-09
JP6811190B2 (ja) 2021-01-13
CN108271373A (zh) 2018-07-10
PH12017502259A1 (en) 2018-06-25
IL255978B (en) 2021-04-29
TWI726889B (zh) 2021-05-11
TN2017000519A1 (en) 2019-04-12
EA036415B1 (ru) 2020-11-09
WO2016198544A1 (en) 2016-12-15
AU2019229424A1 (en) 2019-10-03
SV2017005585A (es) 2018-05-22
CR20170559A (es) 2018-05-11
CN108271373B (zh) 2021-12-28
CL2017003144A1 (es) 2018-04-13
ES2849950T3 (es) 2021-08-24
MY185816A (en) 2021-06-10
CA2988841C (en) 2023-06-06
US20210221866A1 (en) 2021-07-22
EP3307769A1 (en) 2018-04-18
EP3307769B1 (en) 2020-12-02
JP2018518485A (ja) 2018-07-12
SG10201911837SA (en) 2020-01-30
AU2016277449A1 (en) 2018-02-01
KR20180016441A (ko) 2018-02-14
US10414811B2 (en) 2019-09-17

Similar Documents

Publication Publication Date Title
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
MX2016013034A (es) Composicion detergente.
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EP3363458A3 (en) A peptide
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
AR112069A1 (es) Inmunoglobulinas que fijan aggrecan
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2016014633A (es) Nuevos derivados de cath2.
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
BR112016013157A2 (pt) peptídeos resistentes à protease
PH12017500742A1 (en) Statherin peptides
PE20151866A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo
BR112016019389A2 (pt) vacina, e, peptídeo
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
NZ744289A (en) Composition containing amino acids
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
WO2016075305A3 (en) Peptides derived from acinetobacter baumannii and their use in vaccination
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
MX375918B (es) Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis.